Intel stock spikes after report of possible US government stake
Investing.com - TD Cowen has lowered its price target on Humacyte (NASDAQ:HUMA) to $3.50 from $5.00 while maintaining a Buy rating on the biotech company’s stock. Currently trading at $1.89, the stock has seen significant pressure, down over 73% in the past year. According to InvestingPro data, analyst consensus remains bullish with targets ranging from $3.00 to $25.00.
The firm cited mixed progress in the commercial launch of Humacyte’s Symvess product, noting that hospital Value Analysis Committee (VAC) approvals have increased to 13, up from 5 in the first quarter of 2025.
Despite the reduced price target, TD Cowen highlighted improving commercial momentum, with July product sales of approximately $300,000 already exceeding total product sales recorded in the first half of 2025.
The monthly Symvess revenue run rate has increased in the third quarter, according to the research note issued Tuesday.
TD Cowen expressed optimism about this recent improvement in commercial traction and expects sequential revenue growth throughout the second half of 2025 and into 2026.
In other recent news, Humacyte reported its second-quarter 2025 earnings, revealing a notable revenue shortfall and a larger-than-expected loss per share. The company posted revenue of $301,000, falling short of the consensus estimate of $1.01 million. Additionally, Humacyte’s earnings per share came in at -$0.24, missing the forecasted -$0.16. Despite these results, Benchmark reiterated its Buy rating on the company with a price target of $14.00, emphasizing expectations for stronger revenue in the second half of the year. H.C. Wainwright, while maintaining a Buy rating, lowered its price target for Humacyte to $3.00, citing weak sales. BTIG also adjusted its price target to $7.00 from $8.00, following the mixed results. Revenue for the quarter included $100,000 from Symvess product sales and $201,000 from a research collaboration. These developments reflect ongoing challenges and varied analyst perspectives on Humacyte’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.